Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Galapagos 2018. De inhoudelijke discussie.
Volgen
doc-0c-a0-docs.googleusercontent.com/... Conclusion: 'If one JAK inhibitor increases thromboembolic risks, it is likely that others may too – Clinicians prescribing JAK inhibitors for RA should use them cautiously in patients with pre-existing potential thromboembolic risks' Filgotinib gaat dus waarschijnlijk het tegendeel bewijzen en zich onderscheiden.
NielsjeB schreef op 24 augustus 2018 07:50 :
Nice Beurskingpin.
Zuiderbuur heeft in 2017 dat IRAK-inhibitor patent al eens geplaatst [1], maar de PDF daarvan kan ik niet meer openen.
[1]
www.iex.nl/Forum/Post/10012641.aspx worldwide.espacenet.com/publicationDe...
Opop schreef op 25 augustus 2018 22:29 :
doc-0c-a0-docs.googleusercontent.com/... Conclusion:
'If one JAK inhibitor increases thromboembolic risks, it is likely that others may too – Clinicians prescribing JAK inhibitors for RA should use them cautiously in patients with pre-existing potential thromboembolic risks'
Filgotinib gaat dus waarschijnlijk het tegendeel bewijzen en zich onderscheiden.
Link werkt niet meer, vreemd. Artikel in bijlage.
Bridge Biotherapeutics Presented Preclinical Study Results on BBT-877, an Autotaxin inhibitor at the IPF Summit 2018 www.prnewswire.com/news-releases/brid... Ik heb bij Bridge Biotherapeutics de bijbehorende poster opgevraagd, zie bijlage. Ze verwezen me naar een artikel in het Koreaans. Zie de Google Translate vertaling [1]. Het gaat dus om een molecuul dat preklinisch is getest en vergeleken met o.a. GLPG1690. [1] translate.google.com/translate?hl=en&...
Volume 53, Issue S2 The 32nd Annual North American Cystic Fibrosis Conference, Colorado Convention Center, Denver, Colorado, October 18–20, 2018 onlinelibrary.wiley.com/toc/10990496/...
14* RESPONSIVENESS TO CFTR POTENTIATOR DEPENDS ON INTACT R347-D924 INTERACTION
42 THE NEXT GENERATION GALAPAGOS CORRECTOR C2A RESCUES DOMAIN ASSEMBLY OF MUTANT CFTR
186 THE EFFECT OF GALAPAGOS AND ABBVIE TRIPLE CFTR MODULATOR THERAPY ON FORSKOLININDUCED SWELLING OF NASAL AND BRONCHIAL ORGANOIDS FROM CYSTIC FIBROSIS PATIENTS
269 RESULTS FROM A PHASE II STUDY - ALBATROSS - EVALUATION OF GLPG2222 IN SUBJECTS WITH CF AND THE F508DEL/CLASSIII MUTATION ON STABLE TREATMENT WITH IVACAFTOR
271 GLPG2222 IN CF SUBJECTS HOMOZYGOUS FOR F508DEL: RESULTS FROM A PHASE II STUDY (FLAMINGO)
286 DECIPHERING POSSIBLE MECHANISMS OF ACTION OF CFTR CORRECTORS - “AN ABBVIE AND GALAPAGOS EXPERIENCE”
289 EVALUATION OF GALAPAGOS-ABBVIE CFTRMODULATORS USING INTESTINAL ORGANOID ASSAYS
Ik snap er niet zoveel van, toch een AB! m.vr.gr. Ruud
Hele interessante data van BrystelMyerSquib gisteren, zie hieronder analyse van Kempen. BMS LPA1 antagonist gives credence to GLPG1690 target and data GLPG NA 11 September 2018, 08:46 BMS published the results for its terminated phase II trials with LPA1 receptor antagonist (Palmer, 2018), demonstrating a stat sig slowdown in FVC decline in IPF patients, supported by the numerically higher proportion of patients with no decline in FVC. In our view, the results not only provide validation of targeting the ATX-LPA pathway in fibrosis, but also give credence to the observed stabilization of FVC in the phase II FLORA trial with Galapagos' GLPG1690. Meanwhile, the observed safety issues with LPA1 receptor antagonist that led to the termination of the program, were identified as off-target toxicities related to the specific drug profile with no read-through to GLPG1690. We believe if GLPG1690 maintains the magnitude of disease stabilization shown in the FLORA trial, it would be positioned to take the leading market share among second-generation therapies.Efficacy validates LPA as a target in IPF. The phase II study with BMS' LPA1 receptor antagonist BMS-986020 in IPF demonstrated significantly slower rates of FVC decline at 600mg BID dose -42ml vs. -134ml placebo after 26 weeks. The finding was further supported by a numerically higher percentage of patients not experiencing a decline in FVC: 38% vs. 18% The authors concluded that demonstrated results are suggestive of a clinical benefit with LPA1 inhibition in IPF. In our view, the results also provide validation for Galapagos' GLPG1690, an inhibitor of autotaxin - a key enzyme in the production of LPA, and observed stabilization of FVC (+8ml vs. -87ml at w12) in its phase IIa FLORA study, suggesting a biological drug effect rather than random fluctuations of spirometry results.Safety issues are off target, drug-specific. Although the treatment was well tolerated in most patients, the study was terminated prematurely on the evidence of hepatobiliary toxicity as manifested by dose-related elevations in hepatic transaminases and ALP and 3 cases treatment-related cholecystitis. Based on preclinical research, the authors concluded that the liver toxicity was off-target, drug-specific effects related to inhibition of hepatobiliary transporters and bile composition and not related to LPA1 antagonism (Rosen, 2017). The phase II FLORA trial with GLPG1690 and the phase I trial in healthy volunteers did not identify any significant safety and tolerability issues in 17 IPF patients treated with GLPG1690 for 12 weeks: mainly headaches and no signs of hepatotoxicity
Heel goed nieuws, AvantiAvanti, dank! Wanneer worden resultaten FLORA ook weer verwacht, dit jaar nog? Er loopt zoveel, niet bij te houden.
holenbeer schreef op 11 september 2018 11:36 :
Heel goed nieuws, AvantiAvanti, dank! Wanneer worden resultaten FLORA ook weer verwacht, dit jaar nog? Er loopt zoveel, niet bij te houden.
Binnen 2.5 jaar ongeveer, met wat geluk lol..
holenbeer schreef op 11 september 2018 11:36 :
Heel goed nieuws, AvantiAvanti, dank! Wanneer worden resultaten FLORA ook weer verwacht, dit jaar nog? Er loopt zoveel, niet bij te houden.
Publicatie results FLORA phase 2: 9 augustus 2017:www.glpg.com/docs/view/598b6182b414d-en De grote IPF trials met 1500 deelnemers heten Isabella 1 & 2, starten nog dit jaar. Duurt dan nog jaren voordat er resultaten zijn.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)